Izotropic Reaches Q3 Milestones and Provides Engineering Update
Vancouver, British Columbia--(Newsfile Corp. - October 13, 2021) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a Company commercializing a dedicated breast CT (computed tomography) imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers, provides updates on the following:
- Q3 Milestones achieved as scheduled, including 3D imaging reconstruction software implementation, mechanical and electrical design, and clinical study design
- IzoView engineering update
- Meetings with Starfish Medical
Izotropic announced today that it completed noteworthy Q3 2021 milestones as previously announced and is currently ahead of schedule on its Q4 objective to begin the fabrication of IzoView.
Q3 2021 Milestones
- 3D Imaging Reconstruction Software Implementation
Izotropic entered into an agreement with Johns Hopkins University School of Medicine to develop image reconstruction software (deep machine learning algorithms) to further improve the image quality performance of breast CT, as announced earlier this month.
An initial software demonstration has been presented to management and engineering teams and is progressing on schedule to be integrated into the initial IzoView clinical study units.
- Electro-mechanical Designs
The mechanical, electrical, and control systems designs have been completed as scheduled. The Bill of Materials (a complete list of parts required to build the systems) has been completed, and the key components have been sourced and are on site. Additional customized electro-mechanical parts are currently being fabricated.
- Clinical Study Design Finalized
Izotropic, with guidance from Advisor Dr. Craig Abbey, has conducted a number of extensive panel reviews through its partnership with Excite International and has received feedback from potential payor groups and radiologists on the clinical study design. As a result, Izotropic has modified and finalized its clinical study design.
IzoView Engineering Update
With electrical and mechanical designs completed, the fabrication of IzoView is now underway and ahead of schedule.
Under the leadership of Dr. Younes Achkire, VP of Product Engineering, Izotropic has been working closely with Starfish Medical to deliver a device design that will decrease the cost of ownership and minimize operating constraints in real-world settings.
"Great progress has been made on all engineering aspects. Izotropic's engineering teams are moving the focus to industrial design and designing for manufacturability. I am considering all manufacturing processes and lead times and feel confident that testing of IzoView can begin with initial phantom1 3D reconstructions in Q1 2022 as projected," said Dr. Achkire.
Meetings with Starfish Medical
Izotropic's management and engineering teams took advantage of recent changes in provincial and international COVID-19 travel restrictions and organized in-person meetings at Starfish Medical based in Victoria, B.C. Canada. The meetings focused on industrial design prototypes, capital components and parts procurement, timelines, and critical paths to undertake for the completion of the initial IzoView Breast CT device build.
ON BEHALF OF THE COMPANY
Dr. John McGraw, CEO
For investor relations inquiries, contact:
Toll Free: 1-833-IZOCORP ext.1
About Izotropic Corporation
Izotropic Corporation is the only publicly traded company commercializing a dedicated breast CT imaging platform, IzoView, for the more accurate detection and diagnosis of breast cancers. To expedite patient and provider access to IzoView, Izotropic's initial clinical study intends to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. In follow-on clinical studies, Izotropic intends to validate platform applications including breast screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
This document may contain statements that are "Forward-Looking Statements," which are based upon the current estimates, assumptions, projections and expectations of the Company's management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, to identify such information and statements by using words such as "anticipate," "believe," "envision," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate" and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company's activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
1 Phantoms are objects that stand in for human tissue to confirm the device is operating correctly.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99475